Spots Global Cancer Trial Database for astx727
Every month we try and update this database with for astx727 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | NCT06357858 | Recurrent Squam... Metastatic Squa... Head and Neck S... | INQOVI (decitab... Nivolumab | 19 Years - | Case Comprehensive Cancer Center | |
| Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | NCT04953897 | Acute Myeloid L... Myelodysplastic... | ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | NCT02998567 | Castration-Resi... Non Small Cell ... | Guadecitabine Pembrolizumab ASTX727 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT06191978 | Acute Myeloid L... | ASTX727 Venetoclax | 2 Years - 18 Years | M.D. Anderson Cancer Center | |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | NCT06297629 | Allogeneic Stem... | ASTX727 Donor Lymphocyt... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | NCT06113289 | Acute Myeloid L... | ASTX727 ASTX029-01 | 18 Years - | M.D. Anderson Cancer Center | |
| Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors | NCT06177171 | BRCA1 Mutation BRCA2 Mutation BRCA Mutation PALB2 Gene Muta... Checkpoint Kina... ATM Gene Mutati... | Olaparib ASTX727 | 18 Years - | University of California, San Francisco | |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms | NCT06284460 | Pathway Mutant ... Myelodysplastic... Myeloproliferat... | ASTX029 ASTX727 | 18 Years - | M.D. Anderson Cancer Center | |
| Lutathera and ASTX727 in Neuroendocrine Tumours | NCT05178693 | Neuroendocrine ... | ASTX727 Lutathera | 18 Years - 99 Years | Imperial College London | |
| A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | NCT05360160 | Acute Myeloid L... | SNDX-5613 Venetoclax ASTX727 | 12 Years - | M.D. Anderson Cancer Center | |
| A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | NCT06113289 | Acute Myeloid L... | ASTX727 ASTX029-01 | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | NCT06297629 | Allogeneic Stem... | ASTX727 Donor Lymphocyt... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | NCT04953910 | Acute Myeloid L... Myelodysplastic... | ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | NCT04872543 | Malignant Perip... | ASTX727 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | NCT06357858 | Recurrent Squam... Metastatic Squa... Head and Neck S... | INQOVI (decitab... Nivolumab | 19 Years - | Case Comprehensive Cancer Center | |
| Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | NCT02998567 | Castration-Resi... Non Small Cell ... | Guadecitabine Pembrolizumab ASTX727 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | NCT02998567 | Castration-Resi... Non Small Cell ... | Guadecitabine Pembrolizumab ASTX727 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | NCT04872543 | Malignant Perip... | ASTX727 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers | NCT04093570 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... | ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
